Trial · NCT02858310
Results by group73
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 73
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase II: Overall Response Rate Partial Response + Complete Response (PR +CR) | Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells | Complete Response | 0 | Participants | |
| Phase II: Overall Response Rate Partial Response + Complete Response (PR +CR) | Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells | Partial Response | 5 | Participants | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells | Hypoxia-Grade 4- Serious | 0 | toxicities | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells | Hypoxia-Grade 4- Serious | 0 | toxicities | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells | Hypoxia-Grade 4- Serious | 1 | toxicities | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells | Respiratory Failure-Grade 4- Serious | 0 | toxicities | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells | Respiratory Failure-Grade 4- Serious | 0 | toxicities | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells | Respiratory Failure-Grade 4- Serious | 1 | toxicities | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells | Hypotension-Grade 4-Serious | 0 | toxicities | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells | Hypotension-Grade 4-Serious | 0 | toxicities | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells | Hypotension-Grade 4-Serious | 1 | toxicities | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells | Acute Kidney Injury- Grade 4- Serious | 0 | toxicities | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells | Acute Kidney Injury- Grade 4- Serious | 0 | toxicities | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells | Acute Kidney Injury- Grade 4- Serious | 1 | toxicities | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells | Delirium-Grade 3-Serious | 0 | toxicities | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells | Delirium-Grade 3-Serious | 0 | toxicities | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells | Delirium-Grade 3-Serious | 1 | toxicities | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells | Dysphagia-Grade 3-Serious | 0 | toxicities | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells | Dysphagia-Grade 3-Serious | 0 | toxicities | |
| Phase I: Number of Dose Limiting Toxicities (DLT) | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells | Dysphagia-Grade 3-Serious | 1 | toxicities |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02858310/results